PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.
- First Posted Date
- 2007-06-11
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00484718
- Locations
- 🇺🇸
VAPAHCS, Palo Alto, California, United States
🇺🇸Stanford University, Stanford, California, United States
Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 183
- Registration Number
- NCT00484185
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
Study Investigating Rapamune For Post-Marketing Surveillance
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 209
- Registration Number
- NCT00484094
- Locations
- 🇰🇷
Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Yeungnam University Medical Center, Daegu, Korea, Republic of
A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee
Phase 2
Terminated
- Conditions
- Osteoarthritis
- Interventions
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 113
- Registration Number
- NCT00483977
- Locations
- 🇺🇸
Pfizer Investigational Site, Richmond, Virginia, United States
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 338
- Registration Number
- NCT00483756
- Locations
- 🇪🇸
Pfizer Investigational Site, Barcelona, Spain
Effect of a Nasal Bolus Allergen Challenge on Inflammatory Markers
Phase 1
Completed
- Conditions
- Seasonal Allergic Rhinitis
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00483353
- Locations
- 🇬🇧
Pfizer Investigational Site, London, England, United Kingdom
A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients
Phase 3
Terminated
- Conditions
- Obesity
- Interventions
- Behavioral: Non-pharmacological weight loss program (NPP)Behavioral: Low Calorie Diet
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 699
- Registration Number
- NCT00483171
- Locations
- 🇿🇦
Pfizer Investigational Site, Pretoria, South Africa
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3719
- Registration Number
- NCT00483002
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
Not Applicable
Completed
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2008-02-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT00483028
- Locations
- 🇺🇸
Pfizer Investigational Site, Albany, New York, United States
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
Phase 2
Completed
- Conditions
- Sexual Dysfunction, Physiological
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2010-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00482664
- Locations
- 🇸🇪
Pfizer Investigational Site, Stockholm, Sweden
© Copyright 2025. All Rights Reserved by MedPath